Rationale and design of a phase II trial of durvalumab treatment in patients with NSCLC ineligible for stage III chemoradiotherapy following radiation monotherapy (SPIRAL-RT study)

類似資料

• Rationale and design of a phase II study to evaluate prophylactic treatment of dacomitinib-induced dermatologic adverse events in epidermal growth factor receptor-mutated advanced non-small cell lung cancer (SPIRAL-Daco study)
  著者:: Iwasaku, Masahiro, 等
  出版事項: (2019)
• Rationale and design of a phase II trial of osimertinib as first-line treatment for elderly patients with epidermal growth factor receptor mutation-positive advanced non-small cell lung cancer (SPIRAL-0 study)
  著者:: Chihara, Yusuke, 等
  出版事項: (2019)
• Tumor Neovascularization and Developments in Therapeutics
  著者:: Katayama, Yuki, 等
  出版事項: (2019)
• Treatment rationale and design of the SPIRAL study: A phase II trial of osimertinib in elderly epidermal growth factor receptor T790M-positive nonsmall-cell lung cancer patients who progressed during prior EGFR-TKI treatment
  著者:: Uchino, Junji, 等
  出版事項: (2018)
• Safety and Usefulness of Cryobiopsy and Stamp Cytology for the Diagnosis of Peripheral Pulmonary Lesions
  著者:: Imabayashi, Tatsuya, 等
  出版事項: (2019)